Assessing the sensitivity and the clinical impact of the 2023 ACR/EULAR classification criteria in Obstetric Antiphospholid Syndrome: findings from a multicenter Italian cohort with a long-term follow-up

Autoimmune Disease

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions

Arthritis Care Res (Hoboken)

Barbhaiya M, Zuily S, Jannat-Khah D, Amigo MC, Andrade D, Avcin T, Bertolaccini ML, Branch DW, Costedoat-Chalumeau N, de Jesús GR, Devreese KMJ, Garcia D, Gomez Puerta JA, Guillemin F, Levine SR, Levy RA, Lockshin MD, Ortel TL, Petri M, Sanna G, Sciascia S, Seshan SV, Tektonidou M, Wahl D, Willis R, Yelnik C, Hendry A, Naden R, Costenbader KH, Erkan D, New APS Classification Criteria Collaborators

doi: 10.1002/acr.25599

Autoimmune Disease

Assessment of triple antiphospholipid antibody-positive patients based on clinical and laboratory domains of 2023 ACR/EULAR antiphospholipid syndrome classification criteria

Semin Arthritis Rheum

Cobanoglu RK, Vega J, Burgos C, Erkan D

doi: 10.1016/j.semarthrit.2025.152768

Systemic Lupus Erythematosus

Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up

Rheumatology (Oxford)

Michelakis IE, Kapsia E, Boletis JN, Marinaki S, Sfikakis PP, Tektonidou MG

doi: 10.1093/rheumatology/keaf677

Atopic Dermatitis

Impact of Long-term Stability on Mental Health in Adults with Atopic Dermatitis: A Cohort Study with Unsupervised Cluster Analysis

Acta Derm Venereol

Nymand LK, Nielsen ML, Christensen MO, Thomsen SF, Thyssen JP, Egeberg A

doi: 10.2340/actadv.v105.43071

Autoimmune Disease

Recurrent thrombosis and hemorrhagic events in a large single-center primary antiphospholipid syndrome cohort: Results from APS-Rio cohort after nearly 1,000 patient-years of follow-up

Semin Arthritis Rheum

Signorelli F, Balbi GGM, Bastos VP, Reis-Carvalho T, Klumb EM, Levy RA

doi: 10.1016/j.semarthrit.2025.152873

Systemic Sclerosis

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement

Rheumatology (Oxford)

Ross L, Burns AT, La Gerche A, Hansen D, Coghlan JG, Stevens W, Prior D, Pham A, McKelvie P, Bellocchi C, Braun Moscovici Y, Bruni C, Carreira P, Frech T, Hoa S, Hudson M, Hsu V, Hsiu Ling Low A, Matucci-Cerinic M, Medina Fonseca B, Ng SA, Rodriguez Reyna T, Sahhar J, Talaat M, Proudman S, Vacca A, Baron M, Nikpour M, SCTC Cardiac Working Group

doi: 10.1093/rheumatology/keag109

Further Publications Immunology

Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study

J Autoimmun

Bustaffa M, Bella S, Bayindir Y, Amaryan G, Gallizzi R, Papadopoulou-Alataki E, Fabio G, Assalia N, Amarilyo G, Bakkaloglu S, Jesenak M, Breda L, Anton J, Legger E, Alessio M, Simonini G, Rigante D, Obici L, Kuemmerle-Deschner J, Kasapcopur O, Insalaco A, Glerup M, Frenkel J, Brunner J, Horneff G, Sánchez-Manubens J, Cantarini L, Spagnolo A, Alataki S, Carrabba M, Belder N, Porreca A, Caorsi R, Ruperto N, Gattorno M, Ozen S, Eurofever Registry

doi: 10.1016/j.jaut.2025.103421

Further Publications Rheumatology

Assessing clinical and cost effectiveness of total versus partial knee replacement (TOPKAT): 10-year follow-up of a multicentre, randomised controlled trial

Lancet Rheumatol

Beard DJ, Davies LJ, Cook JA, MacLennan G, Hudson J, Price AJ, Carr AJ, Little M, Leal J, Fitzpatrick R, Murray DW, Campbell MK, TOPKAT Study Group

doi: 10.1016/S2665-9913(25)00250-4

Rheumatoid Arthritis

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study

Arthritis Res Ther

Picchianti Diamanti A, Paci V, Luchetti Gentiloni MM, Salemi S, Sesti G, Bellofatto IA, Baldi C, Falsetti P, Chimenti MS, D'Antonio A, Crepaldi G, Zabotti A, Giovannini I, Canzoni M, Fiore D, Sebastiani GD, Scirocco C, Perricone C, Laganà B, Iagnocco A

doi: 10.1186/s13075-025-03671-z

Related content

Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III-C Report: Assessment of Patient Scenarios (Derivation Cohort) and Refinement of Definitions

Assessment of triple antiphospholipid antibody-positive patients based on clinical and laboratory domains of 2023 ACR/EULAR antiphospholipid syndrome classification criteria

Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up

Impact of Long-term Stability on Mental Health in Adults with Atopic Dermatitis: A Cohort Study with Unsupervised Cluster Analysis

Recurrent thrombosis and hemorrhagic events in a large single-center primary antiphospholipid syndrome cohort: Results from APS-Rio cohort after nearly 1,000 patient-years of follow-up

Scleroderma clinical trials consortium classification criteria for systemic sclerosis heart involvement

Long-term efficacy and safety of colchicine and anti-IL-1 blockers in FMF: results from the Eurofever multicenter observational study

Assessing clinical and cost effectiveness of total versus partial knee replacement (TOPKAT): 10-year follow-up of a multicentre, randomised controlled trial

Clinical and ultrasound remission at 48 weeks of upadacitinib in rheumatoid arthritis: real-world results from the Italian multicenter UPARAREMUS study